https://www.fiercepharma.com/pharma/not-just-another-approval-for-merck-s-keytruda-as-nice-signs-off-first-line-nsclc-indication
Keytruda scores key NICE sign-off for first-line NSCLC indication.
"Those who received Keytruda and chemotherpy lived a median 15.9 months, compared to 11.3 months for those on chemo alone, leading to a 36% reduction in the risk of death" Looks like 14 week improvement in survival.
Although this is a step forward I don't think it will be as good as an eftilagimod keytruda trial as first line treatment in this disorder.
And isn't the second line tacti 002 treatment showing better survival?
Overnight Market report, page-104
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.5¢ | $751.3K | 2.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 307462 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 118494 | 4 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |